Compare DERM & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DERM | ORMP |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.9M | 165.3M |
| IPO Year | 2021 | 2010 |
| Metric | DERM | ORMP |
|---|---|---|
| Price | $7.11 | $4.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.67 | N/A |
| AVG Volume (30 Days) | 338.9K | ★ 470.3K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | 34.72 | ★ 412.50 |
| EPS | N/A | ★ 0.91 |
| Revenue | ★ $61,858,000.00 | $2,000,000.00 |
| Revenue This Year | $39.72 | N/A |
| Revenue Next Year | $63.24 | N/A |
| P/E Ratio | ★ N/A | $5.07 |
| Revenue Growth | 10.20 | ★ 49.25 |
| 52 Week Low | $4.31 | $1.98 |
| 52 Week High | $9.56 | $5.19 |
| Indicator | DERM | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 63.54 | 60.59 |
| Support Level | $7.00 | $3.69 |
| Resistance Level | $7.69 | $5.10 |
| Average True Range (ATR) | 0.44 | 0.32 |
| MACD | 0.06 | 0.08 |
| Stochastic Oscillator | 86.21 | 59.09 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.